

3. Kobayashi M, Miki Y, Ebina M, Abe K, Mori K, Narumi S, Suzuki T, Sato I, Maemondo M, Endo C, Inoue A, Kumamoto H, Kondo T, Yamada-Okabe H, Nukiwa T, Sasano H. Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma. *British Journal of Cancer*. 2012;107(10):1745-53.
4. Fujino N, Kubo H, Suzuki T, He M, Suzuki T, Yamada M, Takahashi T, Ota C, Yamaya M. Administration of a specific inhibitor of neutrophil elastase attenuates pulmonary fibrosis after acute lung injury in mice. *Experimental Lung Research*. 2012;38(1):28-36.

砂長 則明 (研究分担者)

1. Sunaga N, Kaira K, Tomizawa Y, Shimizu K, Imai H, Takahashi G, Kakegawa S, Ohtaki Y, Nagashima T, Kasahara N, Kawashima O, Hisada T, Saito R, Yamada M. Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma. *British Journal of Cancer*. 2014;110(8):2047-53.
2. Shimizu K, Kaira K, Tomizawa Y, Sunaga N, Kawashima O, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Yamada M, Oyama T, Takeyoshi I. ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer. *British Journal of Cancer*. 2014;110(8):2030-9.
3. Ohtaki Y, Shimizu K, Kakegawa S, Nagashima T, Nakano T, Atsumi J, Enokida Y, Igai H, Ibe T, Sugano M, Kamiyoshihara M, Kawashima O, Kaira K, Sunaga N, Takeyoshi I. Postrecurrence survival of surgically resected pulmonary adenocarcinoma patients according to and mutation status. *Molecular and Clinical Oncology*. 2014;2(2):187-96.
4. Kotake M, Sato K, Mogi C, Tobo M, Aoki H, Ishizuka T, Sunaga N, Imai H, Kaira K, Hisada T, Yamada M, Okajima F. Acidic pH increases cGMP accumulation through the OGR1/phospholipase C/Ca(2+)/neuronal NOS pathway in N1E-115 neuronal cells. *Cellular signalling*. 2014;26(11):2326-32.
5. Kaira K, Sunose Y, Arakawa K, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Oyama T, Takeyoshi I. Clinicopathological Significance of ASC-Amino Acid Transporter 2 (ASCT2) Expression in Pancreatic Ductal Carcinoma. *Histopathology*. 2014.
6. Ishizuka T, Hisada T, Hatori M, Koike A, Hanabuchi K, Matsuzaki S, Kamide Y, Utsugi M, Aoki H, Yoshino R, Yanagitani N, Koga Y, Ono A, Kaira K, Sunaga N, Dobashi K, Tsuburai T, Akiyama K, Yamada M, Suzuki K, Mori M. Safety and efficacy of high-dose leukocytapheresis in patients with refractory asthma. *Inflammation Research*. 2014;63(9):789-96.
7. Enokida Y, Shimizu K, Kakegawa S, Atsumi J, Takase Y, Miyamae Y, Nagashima T, Ohtaki Y, Kaira K, Sunaga N, Yanagitani N, Yoshino R, Tsunekawa K, Igai H, Kamiyoshihara M, Usui K, Lezhava A, Tomizawa Y, Ishikawa T, Murakami M, Hayashizaki Y, Takeyoshi I. Single-nucleotide polymorphism (c.309T>G) in the gene and lung cancer risk. *Biomedical Reports*. 2014;2(5):719-24.
8. Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. *Oncogene*. 2013;32(34):4034-

42.

9. Nakano S, Gibo J, Fukushima Y, Kaira K, Sunaga N, Taketomi-Takahashi A, Tsushima Y, Mori M. Perfusion evaluation of lung cancer: assessment using dual-input perfusion computed tomography. *Journal of Thoracic Imaging*. 2013;28(4):253-62.
10. Kaira K, Tomizawa Y, Yoshino R, Yoshii A, Matsuura M, Iwasaki Y, Koga Y, Ono A, Nishioka M, Kamide Y, Hisada T, Ishizuka T, Shirai K, Ebara T, Saitoh J, Nakano T, Sunaga N. Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. *Lung Cancer*. 2013;82(3):449-54.
11. Kaira K, Tomizawa Y, Yoshino R, Miura Y, Yoshii A, Iwasaki Y, Koga Y, Ono A, Hisada T, Minato K, Sato K, Kazama T, Ishihara S, Kohyama K, Fueki N, Saito R, Sunaga N. Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer. *Lung Cancer*. 2013;82(1):103-8.
12. Kaira K, Sunose Y, Ohshima Y, Ishioka NS, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, Kanai Y, Yamaguchi A, Segawa A, Ide M, Mori M, Oyama T, Takeyoshi I. Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. *BMC Cancer*. 2013;13:482.
13. Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L, Sato M, Kaira K, Ishizuka T, Gazdar AF, Minna JD, Mori M. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. *International journal of cancer Journal International du Cancer*. 2012;130(8):1733-44.
14. Nakano T, Shimizu K, Kawashima O, Kamiyoshihara M, Kakegawa S, Sugano M, Ibe T, Nagashima T, Kaira K, Sunaga N, Ohtaki Y, Atsumi J, Takeyoshi I. Establishment of a human lung cancer cell line with high metastatic potential to multiple organs: gene expression associated with metastatic potential in human lung cancer. *Oncology Reports*. 2012;28(5):1727-35.
15. Nakajima Y, Takagi H, Kakizaki S, Horiguchi N, Sato K, Sunaga N, Mori M. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells. *Anticancer Research*. 2012;32(12):5251-62.
16. Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, Kanai Y, Segawa A, Furuya M, Mori M, Oyama T, Takeyoshi I. Prognostic significance of L-type amino acid transporter 1 expression in surgically resected pancreatic cancer. *British Journal of Cancer*. 2012;107(4):632-8.

井上 彰 (研究分担者)

1. Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, Isoobe H, Harada M, Ishii Y, Gemma A, Hagiwara K, Kobayashi K. Effectiveness of Gefitinib against Non-Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2014;9(2):189-94.

2. Tsuchihashi T, Mori K, Horie-Inoue K, Okazaki Y, Awata T, Inoue S, Yoneya S. Prognostic phenotypic and genotypic factors associated with photodynamic therapy response in patients with age-related macular degeneration. *Clinical Ophthalmology*. 2014;8:2471-8.
3. Maemondo M, Inoue A, Sugawara S, Harada T, Minegishi Y, Usui K, Miwa K, Morikawa N, Kambe M, Ube K, Watanabe K, Ishimoto O, Sakakibara T, Gemma A, Nukiwa T. Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: North Japan Lung Cancer Group trial 0801. *Oncologist*. 2014;19(4):352-3.
4. Kawashima Y, Inoue A, Sugawara S, Oizumi S, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802. *Respiratory Investigation*. 2014;52(3):190-4.
5. Inoue A, Sugawara S, Harada M, Kobayashi K, Kozuki T, Kuyama S, Maemondo M, Asahina H, Hisamoto A, Nakagawa T, Hotta K, Nukiwa T. Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2014;9(12):1805-9.
6. Gemma A, Kudoh S, Ando M, Ohe Y, Nakagawa K, Johkoh T, Yamazaki N, Arakawa H, Inoue Y, Ebina M, Kusumoto M, Kuwano K, Sakai F, Taniguchi H, Fukuda Y, Seki A, Ishii T, Fukuoka M. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. *Cancer Sci*. 2014;105(12):1584-90.
7. Yanagisawa S, Inoue A, Koarai A, Ono M, Tamai T, Ichinose M. Successful crizotinib retreatment after crizotinib-induced interstitial lung disease. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2013;8(8):e73-4.
8. Sugawara S, Maemondo M, Tachihara M, Inoue A, Ishimoto O, Sakakibara T, Usui K, Watanabe H, Matsubara N, Watanabe K, Kanazawa K, Ishida T, Saijo Y, Nukiwa T, North Japan Lung Cancer Study G. Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601. *Lung cancer*. 2013;81(1):91-6.
9. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, Ohe Y, Nogami N, Takeuchi K, Shimada T, Tanaka T, Tamura T. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. *The Lancet Oncology*. 2013;14(7):590-8.
10. Matsubara N, Maemondo M, Inoue A, Ishimoto O, Watanabe K, Sakakibara T, Fukuhara T, Morikawa N, Tanaka M, Sugawara S, Nukiwa T. Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703. *Respiratory Investigation*. 2013;51(1):28-34.
11. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T, Zaatar A, Osorio

Sanchez JA, Vu VV, Au JS, Inoue A, Lee SM, GebSKI V, Yang JC. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. *Journal of the National Cancer Institute*. 2013;105(9):595-605.

12. Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Kobayashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. *Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology*. 2013;31(27):3335-41.
13. Inoue T, Katoh N, Onimaru R, Shimizu S, Tsuchiya K, Suzuki R, Sakakibara-Konishi J, Shinagawa N, Oizumi S, Shirato H. Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer. *Radiation Oncology*. 2013;8:69.
14. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). *Ann Oncol*. 2013;24(1):54-9.
15. Horiuchi-Yamamoto Y, Gemma A, Taniguchi H, Inoue Y, Sakai F, Johkoh T, Fujimoto K, Kudoh S. Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. *International Journal of Clinical Oncology*. 2013;18(4):743-9.
16. Harada T, Oizumi S, Ito K, Takamura K, Kikuchi E, Kuda T, Sugawara S, Suzuki A, Maemondo M, Fujita Y, Kinoshita I, Inoue A, Hommura F, Katsuura Y, Dosaka-Akita H, Isobe H, Nishimura M, Hokkaido Lung Cancer Clinical Study G. A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901. *Oncologist*. 2013;18(4):439-45.
17. Akamatsu H, Inoue A, Mitsudomi T, Kobayashi K, Nakagawa K, Mori K, Nukiwa T, Nakanishi Y, Yamamoto N. Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405). *Japanese Journal of Clinical Oncology*. 2013;43(6):664-8.
18. Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, Fujita Y, Gemma A, Yamashita Y, Ueno T, Takeuchi K, Choi YL, Miyazawa H, Tanaka T, Hagiwara K, Mano H. A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non-Small Cell Lung Cancer. *Clin Cancer Res*. 2012;18(20):5682-9.
19. Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial. *Oncologist*. 2012;17(6):863-70.
20. Mochizuki S, Nishimura N, Inoue A, Murakami K, Nukiwa T, Chohnabayashi N. Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.

Respiratory Investigation. 2012;50(3):117-21.

21. Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, Gemma A. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2012;7(9):1417-22.
22. Kobayashi M, Miki Y, Ebina M, Abe K, Mori K, Narumi S, Suzuki T, Sato I, Maemondo M, Endo C, Inoue A, Kumamoto H, Kondo T, Yamada-Okabe H, Nukiwa T, Sasano H. Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma. *British Journal of Cancer*. 2012;107(10):1745-53.

---

厚生労働科学研究補助金  
創薬基盤推進研究事業  
高速シーケンサーを用いた包括的臨床遺伝子検査システムの構築  
平成 26 年度 研究報告書

編集, 発行  
平成 27 年 3 月 31 日  
〒 330-8503 埼玉県さいたま市大宮区天沼町 1-847  
自治医科大学附属さいたま医療センター  
総合医学第 1 講座 萩原弘一  
TEL 048-647-2111 ext 6701, FAX 048-644-6262, E-mail hagiwark@me.com

---

